A study analyzing Multiplexed autoantibody (AA) profiling of patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors or platinum-based chemotherapy
Latest Information Update: 31 Mar 2022
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Pharmacodynamics
Most Recent Events
- 31 Mar 2022 New trial record
- 19 Feb 2022 Results (n=53) presented at the 2022 Genitourinary Cancers Symposium.
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium